Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 690517 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Within Dose Groups) and Effect of Food on the Bioavailability of BI 690517 (Openlabel, Randomised, Two-way Cross-over)
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2017
At a glance
- Drugs BI 690517 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 May 2017 Status changed from not yet recruiting to recruiting.
- 02 May 2017 Planned initiation date changed from 27 Apr 2017 to 10 May 2017.
- 06 Apr 2017 New trial record